Genvor Inc (GNVR) — SEC Filings
Genvor Inc (GNVR) — 17 SEC filings. Latest: 10-K (Dec 10, 2025). Includes 6 8-K, 5 10-Q, 3 10-K/A.
Overview
Genvor Inc (GNVR) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a 10-K filed on Dec 10, 2025: Genvor Inc. (GNVR) is an agricultural biotechnology company focused on AI-accelerated peptide technology for sustainable crop protection and performance enhancement. The company reported no revenue for the fiscal year ended September 30, 2025, as it is in the research and development phase, focusing
Sentiment Summary
Across 17 filings, the sentiment breakdown is: 1 bullish, 4 bearish, 11 neutral, 1 mixed. The dominant filing sentiment for Genvor Inc is neutral.
Filing Type Overview
Genvor Inc (GNVR) has filed 2 10-K, 3 10-K/A, 5 10-Q, 6 8-K, 1 8-K/A with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (17)
Risk Profile
Risk Assessment: Of GNVR's 15 recent filings, 4 were flagged as high-risk, 2 as medium-risk, and 9 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $0 |
| Net Income | N/A |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | N/A |
| Operating Margin | N/A |
| Total Assets | N/A |
| Total Debt | N/A |
Key Executives
- Dr. Jesse Jaynes
- Brent Lilienthal
- David L. Miller
- Michael J. DeMarco
Industry Context
Genvor operates in the agricultural biotechnology sector, a rapidly evolving field driven by the need for sustainable solutions to combat crop losses, estimated at $220 billion annually. The industry is characterized by significant R&D investment, a strong emphasis on intellectual property, and increasing adoption of AI for product development. Key trends include the demand for environmentally friendly crop protection methods and performance enhancers, alongside consolidation and strategic partnerships to navigate complex regulatory landscapes and achieve global market penetration.
Top Tags
Genvor Inc. (4) · 10-K/A (3) · Going Concern (3) · 10-Q (3) · SEC Filing (3) · Net Loss (2) · Agriculture (2) · Financial Report (2) · Quarterly Filing (2) · corporate-governance (2)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| estimated annual global crop losses | $220 billion | target market for Genvor's technology |
| improvement in training performance | 85% | BioCypher algorithm's third-generation model |
| proprietary synthetic antimicrobial peptides | 9,000 | integrated into BioCypher algorithm |
| designed peptides | 50,000 | in Genvor's extensive library |
| issued U.S. patents | 5 | part of Genvor's intellectual property portfolio |
| U.S. patent expiration dates | 2031 to 2038 | range for Genvor's current patents |
| shares of common stock outstanding | 34,511,855 | as of December 8, 2025 |
| reduction in fungal growth | 72% | demonstrated by transgenic corn peptide AGM182 in USDA trials |
| reduction in aflatoxin contamination | 98% | demonstrated by transgenic corn peptide AGM182 in USDA trials |
| IC50 for GV185 | 2.1 | against Fusarium graminearum, indicating strong antifungal activity |
| Net Loss | $1,707,481 | for the year ended September 30, 2023, indicating continued unprofitability |
| Revenue | $0 | for the year ended September 30, 2023, highlighting lack of commercial operations |
| Accumulated Deficit | $17,719,307 | as of September 30, 2023, indicating significant historical losses |
| Cash | $44,354 | as of September 30, 2023, a sharp decline from $296,386 in 2022 |
| Net Cash Used in Operating Activities | $871,734 | for the year ended September 30, 2023, demonstrating ongoing cash burn |
Frequently Asked Questions
What are the latest SEC filings for Genvor Inc (GNVR)?
Genvor Inc has 17 recent SEC filings from Jan 2024 to Dec 2025, including 6 8-K, 5 10-Q, 3 10-K/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of GNVR filings?
Across 17 filings, the sentiment breakdown is: 1 bullish, 4 bearish, 11 neutral, 1 mixed. The dominant sentiment is neutral.
Where can I find Genvor Inc SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Genvor Inc (GNVR) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Genvor Inc?
Key financial highlights from Genvor Inc's most recent 10-K include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for GNVR?
The investment thesis for GNVR includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Genvor Inc?
Key executives identified across Genvor Inc's filings include Dr. Jesse Jaynes, Brent Lilienthal, David L. Miller, Michael J. DeMarco.
What are the main risk factors for Genvor Inc stock?
Of GNVR's 15 assessed filings, 4 were flagged high-risk, 2 medium-risk, and 9 low-risk.
What are recent predictions and forward guidance from Genvor Inc?
Forward guidance and predictions for Genvor Inc are extracted from SEC filings as they are enriched.